The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 17, 2012
Filed:
Feb. 07, 2007
Tomohiro Sugimoto, Saitama, JP;
Kanako Yamamoto, Saitama, JP;
Akira Manaka, Saitama, JP;
Haruhisa Ogita, Saitama, JP;
Jun Kurosaka, Saitama, JP;
Madoka Kawamura, Saitama, JP;
Masato Kashimura, Saitama, JP;
Naoki Sasamoto, Saitama, JP;
Tomoaki Miura, Kanagawa, JP;
Kenichi Kanemoto, Kanagawa, JP;
Tomohiro Ozawa, Saitama, JP;
Ken Chikauchi, Chiba, JP;
Eiki Shitara, Kanagawa, JP;
Dai Kubota, Saitama, JP;
Tomohiro Sugimoto, Saitama, JP;
Kanako Yamamoto, Saitama, JP;
Akira Manaka, Saitama, JP;
Haruhisa Ogita, Saitama, JP;
Jun Kurosaka, Saitama, JP;
Madoka Kawamura, Saitama, JP;
Masato Kashimura, Saitama, JP;
Naoki Sasamoto, Saitama, JP;
Tomoaki Miura, Kanagawa, JP;
Kenichi Kanemoto, Kanagawa, JP;
Tomohiro Ozawa, Saitama, JP;
Ken Chikauchi, Chiba, JP;
Eiki Shitara, Kanagawa, JP;
Dai Kubota, Saitama, JP;
Taisho Pharmaceutical Co., Ltd., Tokyo, JP;
Meiji Seika Kaisha, Ltd., Tokyo, JP;
Abstract
[Object]: To provide a compound having a novel structure effective againstand erythromycin resistant bacteria (for example, resistant pneumococci and streptococci) as well as against conventional erythromycin sensitive bacteria. [Solution]: A novel 10a-azalide compound represented by the formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof, or an intermediate for the preparation of the same. The compound of the present invention has superior antibacterial activity against, erythromycin resistant pneumococci and the like, and therefore, the compound can be used as a therapeutic agent of infectious diseases.